[go: up one dir, main page]

AR109135A2 - Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv - Google Patents

Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv

Info

Publication number
AR109135A2
AR109135A2 ARP170102064A ARP170102064A AR109135A2 AR 109135 A2 AR109135 A2 AR 109135A2 AR P170102064 A ARP170102064 A AR P170102064A AR P170102064 A ARP170102064 A AR P170102064A AR 109135 A2 AR109135 A2 AR 109135A2
Authority
AR
Argentina
Prior art keywords
solid form
compound
pirrolidine
dpp
inhibiting
Prior art date
Application number
ARP170102064A
Other languages
English (en)
Inventor
Julie M Cherrington
David Alan Campbell
Zhen-Ping Wu
Original Assignee
Phenomix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomix Corp filed Critical Phenomix Corp
Publication of AR109135A2 publication Critical patent/AR109135A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina, caracterizada porque el compuesto de pirrolidina tiene la fórmula (1) o una forma cíclica de la misma, de fórmula (2), o una mezcla de las mismas, donde la forma sólida comprende entre 8 y 14% en peso de agua y es sustancialmente no higroscópica cuando se la expone a la atmósfera a una humedad relativa de hasta entre 40 y 60% a 25ºC.
ARP170102064A 2006-08-30 2017-07-21 Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv AR109135A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84109706P 2006-08-30 2006-08-30

Publications (1)

Publication Number Publication Date
AR109135A2 true AR109135A2 (es) 2018-10-31

Family

ID=39136484

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070103842A AR062590A1 (es) 2006-08-30 2007-08-29 Sales solidas de citrato y tartrato de inhibidores de dpp-iv, preparacion de las mismas, una composicion y una combinacion farmaceutica que las comprenden y el uso de las mismas en trastornos del control de la glucemia.
ARP170102064A AR109135A2 (es) 2006-08-30 2017-07-21 Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070103842A AR062590A1 (es) 2006-08-30 2007-08-29 Sales solidas de citrato y tartrato de inhibidores de dpp-iv, preparacion de las mismas, una composicion y una combinacion farmaceutica que las comprenden y el uso de las mismas en trastornos del control de la glucemia.

Country Status (18)

Country Link
US (1) US8299271B2 (es)
EP (1) EP2061474A4 (es)
JP (1) JP5264728B2 (es)
KR (1) KR101504769B1 (es)
CN (1) CN101522201B (es)
AR (2) AR062590A1 (es)
AU (1) AU2007290684B2 (es)
BR (1) BRPI0715447B8 (es)
CA (1) CA2661776C (es)
CL (1) CL2007002499A1 (es)
EA (1) EA017833B1 (es)
HK (1) HK1134248A1 (es)
IL (2) IL197225A (es)
MX (1) MX2009002281A (es)
NO (1) NO20091291L (es)
TW (1) TW200817324A (es)
WO (1) WO2008027273A2 (es)
ZA (1) ZA200901510B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN103497232A (zh) * 2008-06-17 2014-01-08 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
KR20160143897A (ko) 2009-02-13 2016-12-14 베링거 인겔하임 인터내셔날 게엠베하 Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102286011B (zh) * 2010-03-16 2017-10-03 美德（江西）生物科技有限公司 吡咯烷硼酸酯二肽基肽酶抑制剂及其药物组合物
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2601181A1 (de) * 2010-08-05 2013-06-12 Boehringer Ingelheim International GmbH Säureadditionssalze des 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl]acetamids und ihre verwendung als bradykinin-b1 rezeptor antagonisten
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103483363B (zh) * 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
JP2014129255A (ja) * 2012-12-28 2014-07-10 Fujifilm Corp 組成物およびフィルムならびにそれらの製造方法
TN2016000492A1 (en) 2014-05-20 2018-04-04 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy.
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
KR101978364B1 (ko) 2017-06-15 2019-05-14 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법
KR102678356B1 (ko) 2018-10-29 2024-06-26 씨지인바이츠 주식회사 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 인산염, 타르타르산염 또는 이들의 조합을 포함하는 약제학적 조성물 및 그 제조방법
CN111537622B (zh) * 2019-11-29 2021-11-26 杭州华东医药集团新药研究院有限公司 一种度格列汀及其盐的杂质的检测方法
CN111533675B (zh) * 2019-11-29 2021-09-28 杭州华东医药集团新药研究院有限公司 杂环硼酸化合物的杂质及其控制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109681A2 (en) 2007-03-08 2008-09-12 Phenomix Corporation Methods and intermediates for synthesis of selective dpp-iv inhibitors
EP1743676A1 (en) * 2003-11-12 2007-01-17 Phenomix Corporation Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
AU2006275697A1 (en) 2005-08-01 2007-02-08 Phenomix Corporation Methods of preparing hetercyclic boronic acids and derivatives thereof
PE20080668A1 (es) 2006-08-30 2008-07-17 Novartis Ag Compuestos heterociclicos como inhibidores de la cinasa-2 de proteina activada por cinasa de proteina activada por mitogeno
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
CN101506148A (zh) 2006-08-30 2009-08-12 弗·哈夫曼-拉罗切有限公司 Glyt-1的抑制剂
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.

Also Published As

Publication number Publication date
BRPI0715447B8 (pt) 2021-05-25
BRPI0715447A2 (pt) 2014-05-06
TW200817324A (en) 2008-04-16
AU2007290684B2 (en) 2012-08-16
EA017833B1 (ru) 2013-03-29
IL242267A (en) 2017-12-31
BRPI0715447B1 (pt) 2020-09-15
CN101522201B (zh) 2015-08-19
CA2661776A1 (en) 2008-03-06
JP5264728B2 (ja) 2013-08-14
IL197225A (en) 2015-11-30
CA2661776C (en) 2015-03-24
CN101522201A (zh) 2009-09-02
KR101504769B1 (ko) 2015-03-20
JP2010502610A (ja) 2010-01-28
IL197225A0 (en) 2009-12-24
IL242267A0 (en) 2015-11-30
US8299271B2 (en) 2012-10-30
EP2061474A4 (en) 2011-06-15
US20100323988A1 (en) 2010-12-23
WO2008027273A3 (en) 2008-07-31
KR20090043601A (ko) 2009-05-06
CL2007002499A1 (es) 2008-03-14
WO2008027273A2 (en) 2008-03-06
EA200900375A1 (ru) 2009-10-30
AR062590A1 (es) 2008-11-19
ZA200901510B (en) 2010-05-26
MX2009002281A (es) 2009-05-20
NO20091291L (no) 2009-03-27
EP2061474A2 (en) 2009-05-27
HK1134248A1 (zh) 2010-04-23
AU2007290684A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
AR109135A2 (es) Forma sólida de una sal hidratada de tartrato de un compuesto de pirrolidina inhibidor de dpp-iv
EA201070786A1 (ru) Бензофуропиримидиноны
AR112532A2 (es) Compuestos de tetraciclina sustituidos con flúor en c7
HRP20120323T1 (en) Diarylhydantoin compounds
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
SMAP200900013A (it) Peptidomimetici smac utili come inibitori di iap
NO20071880L (no) Diagnostic Compounds
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
CO6390081A2 (es) Compuestos organicos
CO6612278A2 (es) Composición acuosa antitranspirante/desodorante
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
DK2074120T3 (da) Tropan-forbindelser
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
AR061134A1 (es) Derivados de tioxantina
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
UY29857A1 (es) Derivados de la 4-amino-quinazolina, su preparación y su aplicación en terapéutica.
MEP10209A (en) Stable emulsion composition
NO20085317L (no) Imidazoazepinonforbindelser
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer
UY30788A1 (es) Compuestos quimicos
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
CR9565A (es) Derivados del 4,5-diarilpirrol, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure